Micro Labs

What Micro Labs does

Micro Labs Limited is a privately held Indian pharmaceutical company headquartered in Bangalore, founded in 1973 by G.C. Surana and led by the Surana family across Chairman & Managing Director, Director, and Head of Corporate Affairs roles. The company manufactures Active Pharmaceutical Ingredients at a 24,000 square meter facility and produces finished dosage formulations across 14 cGMP-compliant manufacturing plants in India, holding US FDA and UK MHRA accreditations that enable access to regulated international markets.

Micro Labs sells branded generic pharmaceuticals across cardiovascular, anti-infective, neurological, gastrointestinal, and dermatological therapy segments, distributed to over 50 countries with ground-level operations in 25 markets. Its flagship brand, Dolo-650, ranks as the 6th largest brand in the Indian Pharmaceutical Market per AWACS and the number one prescribed paracetamol solid oral brand in India. The company has expanded into OTC wellness under the Micro Wellness sub-brand (pain relief sprays, cough lozenges, thermometers, antacids, nicotine gums) and launched Trisopt, the world's first triple-drug fixed-dose combination for glaucoma management. In October 2024, Micro Labs acquired Nigerian pharmaceutical company Swipha to establish an African foothold.

Revenue is generated primarily through one-time sale of pharmaceutical formulations and APIs to healthcare providers, pharmacies, and other pharmaceutical companies, complemented by OTC retail distribution domestically and through channel partners internationally. Go-to-market combines a field sales force targeting medical practitioners in India with direct international distribution to regulated and emerging markets. The company also functions as a strategic corporate investor, deploying capital into India's venture debt market and regional aviation in late 2025.

Name

Micro Labs

Legal name

Micro Labs Limited

Website

https://microlabsltd.com

Company type

Private

Founded year

1973

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Micro Labs is a privately held Indian pharmaceutical company, founded in 1973 and headquartered in Bangalore, that manufactures APIs and formulations across 14 cGMP plants and sells branded generics including Dolo-650 to healthcare providers, patients, and distributors in over 50 countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Generic pharmaceuticals
• Active pharmaceutical ingredients
• Branded formulations
• OTC wellness products
• Cardiovascular medications

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Formulations: Sale of branded generic pharmaceutical drugs including cardiovascular, anti-infective, neurological, gastrointestinal, dermatological, and other therapeutic segments.
2. Active Pharmaceutical Ingredients (API): Manufacturing and sale of APIs to other pharmaceutical companies; API unit built over 24,000 square meters.
3. OTC/Wellness Products: Over-the-counter products under Micro Wellness brand including pain relief sprays, lozenges, thermometers, antacids, and nicotine gums.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Micro Labs manufactures and sells Active Pharmaceutical Ingredients (APIs) and finished dosage formulations across multiple therapeutic segments including cardiovascular, anti-infective, neurological, gastrointestinal, dermatological, and diabetes therapies. The company operates 14 cGMP-compliant manufacturing plants in India, holds US FDA and UK MHRA accreditations, and distributes branded prescription pharmaceuticals (e.g., Dolo-650, Trisopt) and OTC wellness products (under the Micro Wellness brand) to over 50 countries with ground operations in 25 countries.

Product overview

Micro Labs is an Indian pharmaceutical company operating as a single unified product portfolio spanning the entire pharmaceutical value chain. The company manufactures Active Pharmaceutical Ingredients (API) at its 24,000 sq meter facility, produces finished dosage formulations across 14 cGMP-compliant plants, and distributes a comprehensive range of branded pharmaceutical products. Key branded products include Dolo-650 (paracetamol, the 6th largest brand in India), Trisopt (world's first triple-drug combination for glaucoma), and multiple cardiovascular and diabetes medications. The company has expanded into the OTC wellness segment under the Micro Wellness sub-brand with products like pain relief sprays, cough lozenges, and thermometers. Through its acquisition of Swipha in Nigeria, Micro Labs has extended its presence into the African pharmaceutical market.

Differentiator

Problem solved

Functional benefit

Brands

• Dolo: Micro Labs' flagship pharmaceutical brand; Dolo-650 (paracetamol) is the 6th largest brand in the Indian Pharmaceutical Market and the number one prescribed brand of paracetamol solid oral doses in India. The brand has been expanded into OTC space including pain relief spray, cough lozenges, and other wellness products.

Products and services

• Dolo-650 Branded paracetamol solid oral dose formulation; the 6th largest brand in the Indian Pharmaceutical Market (per AWACS) and the number one prescribed brand of paracetamol solid oral doses in India. Used by medical professionals and patients for fever and pain relief.
• Trisopt

Quantifiable outcome

• Dolo-650 ranked 6th largest brand in Indian Pharmaceutical Market (per AWACS)
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Swipha (Swiss Pharma Nigeria Limited)coreStrategic or Co-development Partner · 15 October 2024Micro Labs acquired Swipha, a leading pharmaceutical company in Nigeria, to expand its footprint across the African continent. The acquisition improves supply chain efficiency, broadens treatment options, and facilitates product export to neighboring countries.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Mankind Pharma: Indian branded generics company with comparable therapeutic breadth and a similarly aggressive OTC/consumer wellness strategy (e.g., Manforce, Prega News). Closest analog to Micro Labs in terms of domestic prescription strength and OTC brand extension.
• Alkem Laboratories: Indian pharma company with a comparable branded-generics portfolio spanning anti-infectives, cardiology, GI, and dermatology, plus manufacturing scale across multiple cGMP plants. Closely matches Micro Labs on therapeutic mix and domestic prescription footprint.
• Torrent Pharmaceuticals: Mid-sized Indian pharma with a strong branded generics portfolio in cardiovascular, diabetes, and CNS — overlapping heavily with Micro Labs' cardiovascular (Amlong/Arbitel) and diabetes (Diapride/Tripride) franchises.
• JB Chemicals & Pharmaceuticals: Indian branded generics player with similar scale, multi-therapeutic presence, and growing OTC/consumer health line. Comparable in plant footprint and regulatory maturity to Micro Labs.
• Ipca Laboratories: Indian pharma manufacturer with overlapping therapeutic areas (anti-infectives, cardiovascular, pain management) and parallel API manufacturing capabilities — directly comparable vertically integrated model to Micro Labs.
• Emcure Pharmaceuticals: Mid-sized Indian pharma with comparable branded generics footprint across women's health, cardiology, and anti-infectives, plus growing international presence. Closely matched in scale and ambition to Micro Labs.

Broad incumbents

• Cipla: Large incumbent Indian pharma with a much broader portfolio and global footprint but overlapping therapeutic segments (respiratory, cardiovascular, anti-infectives). Sets the competitive ceiling on branded generics in India.
• Sun Pharmaceutical Industries: India's largest pharma company, dominant in chronic therapy branded generics including cardiology and neurology — segments where Micro Labs also competes. Sets pricing and doctor-engagement benchmarks.
• Dr. Reddy's Laboratories: Major Indian pharma with parallel API + generics model and significant regulated-market exports (US, EU). Comparable API manufacturing depth to Micro Labs' 24,000 sqm API facility.
• Lupin Limited: Large Indian pharma with strong branded generics in cardiovascular, anti-infectives, and diabetes — all therapeutic pillars where Micro Labs operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/microlabsltd
• LinkedInlinkedin.com/company/119172
• Facebookfacebook.com/caripill1100

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micro Labs